No abstract available
Publication types
-
Clinical Trial, Phase II
-
Letter
-
Multicenter Study
MeSH terms
-
Adult
-
Aged
-
Antineoplastic Agents / therapeutic use
-
Area Under Curve
-
Boronic Acids / therapeutic use
-
Bortezomib
-
Diarrhea / chemically induced
-
Drug Administration Schedule
-
Drug Resistance, Neoplasm
-
Female
-
Histone Deacetylase Inhibitors / adverse effects
-
Histone Deacetylase Inhibitors / pharmacokinetics
-
Histone Deacetylase Inhibitors / therapeutic use*
-
Humans
-
Hydroxamic Acids / adverse effects
-
Hydroxamic Acids / pharmacokinetics
-
Hydroxamic Acids / therapeutic use*
-
Indoles / adverse effects
-
Indoles / pharmacokinetics
-
Indoles / therapeutic use*
-
Lenalidomide
-
Male
-
Metabolic Clearance Rate
-
Middle Aged
-
Multiple Myeloma / drug therapy*
-
Multiple Myeloma / metabolism
-
Multiple Myeloma / pathology
-
Nausea / chemically induced
-
Neutropenia / chemically induced
-
Panobinostat
-
Pyrazines / therapeutic use
-
Recurrence
-
Remission Induction
-
Thalidomide / analogs & derivatives
-
Thalidomide / therapeutic use
-
Thrombocytopenia / chemically induced
-
Treatment Outcome
Substances
-
Antineoplastic Agents
-
Boronic Acids
-
Histone Deacetylase Inhibitors
-
Hydroxamic Acids
-
Indoles
-
Pyrazines
-
Thalidomide
-
Bortezomib
-
Panobinostat
-
Lenalidomide